Skip to content
Review

Abstract 15552: Ketamine versus Etomidate for Emergency Tracheal Intubation in Critically Ill Adults: A Systematic Review and Meta-Analysis of Randomized Trials

Nov 2026 · Circulation · 0 citations

Abstract

Introduction/Background: Ketamine and etomidate are the most commonly used induction agents for emergency tracheal intubation in critically ill adults. However, their comparative cardiovascular safety remains uncertain. Research Questions/Hypothesis: To compare peri-intubation cardiovascular and mortality outcomes between ketamine and etomidate in randomized controlled trials. Methods/Approach: PubMed, Embase, and Cochrane databases were systematically searched for randomized controlled trials comparing ketamine and etomidate for endotracheal intubation in critically ill adults. Outcomes of interest included mortality, peri-intubation cardiac arrest, hypotension, and cardiovascular collapse. Pooled risk ratios (RRs) with 95% confidence intervals (CIs) were calculated using random-effects models. Statistical heterogeneity was assessed using the I 2 statistic, and leave-one-out sensitivity analyses were performed to evaluate the robustness of the results. Statistical analysis was performed using R (RStudio version 2026.01.0, Build 392). Results/Data: Five RCTs involving 4,028 critically ill patients (2,006 randomized to ketamine and 2,022 to etomidate) were included. Ketamine was not associated with significant differences in all-cause mortality (RR 0.95, 95% CI 0.84-1.07; I 2 =20%), peri-intubation cardiac arrest (RR 1.29, 95% CI 0.77-2.16; I 2 =0%), hypotension (RR 1.10, 95% CI 0.85-1.43; I 2 =0%), or cardiovascular collapse (RR 0.99, 95% CI 0.79-1.23; I 2 =0%) compared with etomidate. Sensitivity analyses yielded consistent results across all outcomes. Conclusion: Among critically ill adults undergoing emergency endotracheal intubation, ketamine and etomidate were associated with similar risks of mortality, peri-intubation cardiac arrest, hypotension, and cardiovascular collapse. Current randomized evidence does not support the superiority of either induction agent with respect to major cardiovascular or clinical outcomes.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.